During the last session, Candel Therapeutics Inc (NASDAQ:CADL)’s traded shares were 1.24 million, with the beta value of the company hitting -1.12. At the end of the trading day, the stock’s price was $8.68, reflecting an intraday gain of 9.18% or $0.73. The 52-week high for the CADL share is $14.60, that puts it down -68.2 from that peak though still a striking 86.64% gain since the share price plummeted to a 52-week low of $1.16. The company’s market capitalization is $421.50M, and the average intraday trading volume over the past 10 days was 3.72 million shares, and the average trade volume was 3.39 million shares over the past three months.
Candel Therapeutics Inc (CADL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CADL has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Candel Therapeutics Inc (CADL) registered a 9.18% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 9.18% in intraday trading to $8.68, hitting a weekly high. The stock’s 5-day price performance is 0.58%, and it has moved by 84.48% in 30 days. Based on these gigs, the overall price performance for the year is 490.48%. The short interest in Candel Therapeutics Inc (NASDAQ:CADL) is 1.78 million shares and it means that shorts have 7.72 day(s) to cover.
Candel Therapeutics Inc (CADL) estimates and forecasts
Statistics show that Candel Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Candel Therapeutics Inc (CADL) shares have gone up 38.88% during the last six months, with a year-to-date growth rate less than the industry average at -21.37% against 16.70.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -46.75%. While earnings are projected to return -21.37% in 2025.
CADL Dividends
Candel Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
Candel Therapeutics Inc insiders own 30.39% of total outstanding shares while institutional holders control 22.53%, with the float percentage being 32.37%. NORTHPOND VENTURES, LLC is the largest shareholder of the company, while 74.0 institutions own stock in it. As of 2024-06-30, the company held over 1.94 million shares (or 6.628% of all shares), a total value of $12.0 million in shares.
The next largest institutional holding, with 0.82 million shares, is of BLACKROCK INC.’s that is approximately 2.819% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.1 million.
